Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down - Should You Sell?

Key Points

• Price action: Astellas gapped down pre-market from $16.48 to $15.87 and was last trading around $16.28, about a 1.0% decline on roughly 25,124 shares.
• Analyst sentiment: Brokerages are mixed — one Strong Buy and four Hold ratings leave an average rating of "Hold," with recent moves from Citigroup, SMBC Nikko and Jefferies.
• Earnings beat: The company topped expectations with Q results of $0.44 EPS versus $0.29 expected and revenue of $3.67B versus $3.21B, while trading at a PE near 13.6 and a market cap of ~$29.35B.

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $16.48, but opened at $15.87. Astellas Pharma shares last traded at $16.28, with a volume of 25,124 shares trading hands.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALPMY. Citigroup cut shares of Astellas Pharma from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 19th. Smbc Nikko Sec. upgraded Astellas Pharma to a "hold" rating in a research report on Monday, February 16th. Finally, Jefferies Financial Group upgraded Astellas Pharma from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold".

Astellas Pharma Stock Down 1.0%

The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23. The business has a 50-day moving average price of $15.55 and a 200-day moving average price of $13.44. The firm has a market capitalization of $29.35 billion, a PE ratio of 13.63 and a beta of 0.17.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.15. The company had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.21 billion. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%. Equities research analysts forecast that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas' portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.